VANCOUVER, British Columbia, June 17 /CNW/ -- Xenon Pharmaceuticals Inc.,
a drug discovery and development company, is pleased to announce today that it
has been awarded the Promising Early Stage Company of the Year Award by
BIOTECanada in the Health category for 2008.
"We are delighted to have received this prestigious award, one of
BIOTECanada's four Gold Leaf Awards presented this year," commented Simon
Pimstone, Xenon's President and CEO. "This honor is important and made even
more so by the fact that it represents recognition by our industry peers of
both our achievements to date and the potential that Xenon offers."
"Xenon has made substantial progress in advancing its pipeline of novel
compounds acting against targets derived from our clinical genetics approach.
In the next 12 months we should have multiple products in clinical development
for potential blockbuster markets. Our product pipeline is diverse, and we
are excited to be advancing our discoveries into clinical opportunities,"
About Xenon Pharmaceuticals Inc.
Xenon is a privately owned, clinical genetics-based drug discovery and
development company engaged in developing small molecule therapies focusing in
pain, lipid modification for treating diabetes/obesity and other diseases, as
well as therapies for treating anemia and diseases of iron overload. Xenon
has partnerships with Novartis Pharma AG, Roche and Takeda Pharmaceutical
Company Ltd. For more information, visit the Company's website at
For further information:
For further information: Dr. Simon Pimstone, President & CEO of Xenon
Pharmaceuticals Inc., +1-604-484-3300, email@example.com Web Site: